<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00804531</url>
  </required_header>
  <id_info>
    <org_study_id>P070157</org_study_id>
    <nct_id>NCT00804531</nct_id>
  </id_info>
  <brief_title>Intra-discal Steroid Injection for MODIC I Discopathy</brief_title>
  <acronym>PREDID</acronym>
  <official_title>Intra-discal Steroid Injection for MODIC I Discopathy: A Randomized Control Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assistance Publique - Hôpitaux de Paris</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Assistance Publique - Hôpitaux de Paris</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To assess the efficacy on pain level at 1 month and 12 months of a steroid injection in the
      inter-vertebral disc for patients with chronic back pain and inflammatory discopathy on
      magnetic resonance imaging.

      Hypothesis: delivering anti-inflammatory drugs in situ may decrease back pain in patients
      with inflammatory discopathy
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Objective: to assess the efficacy on pain level of a steroid injection in the inter-vertebral
      disc for patients with chronic back pain and MODIC I discopathy on MRI

      Methods: a multicenter double blind randomized control trial Setting: 3 tertiary care
      hospitals in France Patients: 134 patients with disabling chronic low back pain not relieved
      by usual recommended treatments and MODIC I (inflammatory) discopathy on MRI Intervention:
      Injection of 25 mg of methylprednisolone in the inter-vertebral disc during a discography
      (intervention group, 67 patients) or discography alone (control group, 67 patients) Outcome
      measures: The primary outcome measure is pain level assessed on a 11-point numeric scale
      (0-100) at 1 month. Success is defined as less than 40 on pain numeric scale at 1 month.
      Secondary outcome measures are pain level at 12 months, Disability (Quebec questionnaire),
      quality of life (SF-12) at 1 and 12 months, anxiety and depression (HAD), analgesics and
      anti-inflammatories during the last week, return to work, assessment of the disabilities at 1
      and 12 months and disc inflammation (on MRI) at 12 months. Tolerance and adverse effects will
      be recorded.

      Trial duration: 36 months(24 months for inclusion and 12 months follow-up) Follow-up visits:
      at 1, 3, 6, and 12 months Statistical analysis: intention to treat
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2009</start_date>
  <completion_date type="Actual">November 2015</completion_date>
  <primary_completion_date type="Actual">May 2015</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Back pain level assessed on a 11-point numeric scale (0-100) at 1 month. Success is defined as less than 40 on pain numeric scale at 1 month</measure>
    <time_frame>1 month</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>pain level at 12 months</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disability (Quebec questionnaire)</measure>
    <time_frame>1 month and 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>quality of life (SF-12) at 1 and 12 months</measure>
    <time_frame>1 month and 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>anxiety and depression (HAD)</measure>
    <time_frame>1 month and 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>disc inflammation (on MRI) at 12 month</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>analgesics and anti-inflammatories during the last week</measure>
    <time_frame>1 month and 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>return to work</measure>
    <time_frame>1 month and 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of the disabilities (scale of 6 classes)</measure>
    <time_frame>1 month and 12 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">137</enrollment>
  <condition>Back Pain Lower Back Chronic</condition>
  <arm_group>
    <arm_group_label>Visipaque - Hydrocortancyl</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Administration of two treatments for the experimental arm</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Visipaque</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Administration of only one treatment in intra discal of visipaque</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Visipaque - Hydrocortancyl</intervention_name>
    <description>Visipaque 320 mg I/ml - 1 ml intra-discal route Hydrocortancyl 25 mg/ml - 1 ml intra-discal route</description>
    <arm_group_label>Visipaque - Hydrocortancyl</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo comparator</intervention_name>
    <description>Visipaque - 320 mg I/ml - 1 ml in intra-discal route</description>
    <arm_group_label>Visipaque</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria :

          -  More than 18 and less than 70 years old

          -  Low back pain

          -  Daily pain for at least 3 months

          -  Pain level during the last 48 hours &gt; 40 on the numeric pain scale (0-100)

          -  Lack of efficacy of usual recommended treatments and of other spine steroid injections
             (epidural or facet joints injections)

          -  Modic I discopathy on MRI

          -  Intra-discal injection at least 6 months before inclusion

          -  Written informed consent

          -  Social security

          -  Medical examination

        Non inclusion criteria :

          -  Pregnancy

          -  Hypersensitivity to methylprednisolone or contrast

          -  Local or general infection

          -  Previous disc surgery less than 6 months

          -  Steroid treatment

          -  Previous infectious spondylodiscitis

          -  Ankylosing spondylitis

          -  Sciatica with neurologic defects

          -  Uncontrolled psychiatric conditions

          -  Inability to read or understand French language

          -  Anti-vitamin K treatments

          -  Severe coagulation diseases

          -  Fever &gt; 38 or sedimentation rate &gt; 20

          -  Discopathy with MODIC 1 signal on several different lumbar stages
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Serge Poiraudeau, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Assistance Publique - Hôpitaux de Paris</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hôpital Cochin</name>
      <address>
        <city>Paris</city>
        <zip>75014</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <results_reference>
    <citation>Nguyen C, Boutron I, Baron G, Sanchez K, Palazzo C, Benchimol R, Paris G, James-Belin É, Lefèvre-Colau MM, Beaudreuil J, Laredo JD, Béra-Louville A, Cotten A, Drapé JL, Feydy A, Ravaud P, Rannou F, Poiraudeau S. Intradiscal Glucocorticoid Injection for Patients With Chronic Low Back Pain Associated With Active Discopathy: A Randomized Trial. Ann Intern Med. 2017 Apr 18;166(8):547-556. doi: 10.7326/M16-1700. Epub 2017 Mar 21.</citation>
    <PMID>28319997</PMID>
  </results_reference>
  <verification_date>May 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 8, 2008</study_first_submitted>
  <study_first_submitted_qc>December 8, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 9, 2008</study_first_posted>
  <last_update_submitted>August 11, 2017</last_update_submitted>
  <last_update_submitted_qc>August 11, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">August 14, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Low back pain</keyword>
  <keyword>steroid injection</keyword>
  <keyword>inter-vertebral disc</keyword>
  <keyword>randomized trial</keyword>
  <keyword>Lack of efficacy of usual recommended treatments</keyword>
  <keyword>More than 40 on the pain numeric scale (0-100)</keyword>
  <keyword>Inflammatory discopathy (MODIC I) on MRI</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Back Pain</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prednisolone acetate</mesh_term>
    <mesh_term>Methylprednisolone acetate</mesh_term>
    <mesh_term>Methylprednisolone</mesh_term>
    <mesh_term>Methylprednisolone Hemisuccinate</mesh_term>
    <mesh_term>Prednisolone</mesh_term>
    <mesh_term>Prednisolone hemisuccinate</mesh_term>
    <mesh_term>Prednisolone phosphate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

